The objective of this exploratory study is to evaluate, for the first time, the sensitivity of 18F-Fludarabine to the initial diagnosis of MM compared to FDG-PET and MRI. The interest of this molecule will also be investigated as part of the end-of-treatment therapeutic evaluation.
Symptomatic MM in the first line in patients who are not candidates for autologous bone marrow transplantation.
Patients eligible for one of the treatments considered as standard in a patient who is not eligible for autograft, according to ESMO's European recommendations
MM with measurable disease either by the serum evaluation of the monoclonal component or by the determination of free light chains (serum or urinary).
Patient affiliated with a social insurance scheme
Age under 18 years
Pregnancy or breastfeeding
Male or female refusing birth control conditions
Primary AL amyloidosis and myeloma complicated by amyloidosis
Nantes University Hospital
Lead sponsor
Cyceron
Collaborator